PL445027A1 - Sposób diagnozowania stwardnienia rozsianego in vitro - Google Patents

Sposób diagnozowania stwardnienia rozsianego in vitro

Info

Publication number
PL445027A1
PL445027A1 PL445027A PL44502723A PL445027A1 PL 445027 A1 PL445027 A1 PL 445027A1 PL 445027 A PL445027 A PL 445027A PL 44502723 A PL44502723 A PL 44502723A PL 445027 A1 PL445027 A1 PL 445027A1
Authority
PL
Poland
Prior art keywords
vitro
multiple sclerosis
diagnosing multiple
sclerosis
diagnosing
Prior art date
Application number
PL445027A
Other languages
English (en)
Inventor
Przemysław Lewkowicz
Paweł Piątek
Magdalena Namiecińska
Original Assignee
Uniwersytet Medyczny w Łodzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny w Łodzi filed Critical Uniwersytet Medyczny w Łodzi
Priority to PL445027A priority Critical patent/PL445027A1/pl
Priority to EP24748453.8A priority patent/EP4720674A1/en
Priority to PCT/PL2024/050037 priority patent/WO2024248642A1/en
Publication of PL445027A1 publication Critical patent/PL445027A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ecology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Zgłoszenie dotyczy sposobu diagnozowania stwardnienia rozsianego (łac. Sclerosis Multiplex, — SM) in vitro w oparciu o bezwzględną liczbę limfocytów o fenotypie CD49d+CD154+ autoreaktywnych w stosunku do białek mieliny po ekspozycji komórek jednojądrzastych krwi obwodowej na peptydy mieliny w warunkach in vitro. Sposób jest użyteczny we wczesnym rozpoznaniu stwardnienia rozsianego.
PL445027A 2023-05-29 2023-05-29 Sposób diagnozowania stwardnienia rozsianego in vitro PL445027A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL445027A PL445027A1 (pl) 2023-05-29 2023-05-29 Sposób diagnozowania stwardnienia rozsianego in vitro
EP24748453.8A EP4720674A1 (en) 2023-05-29 2024-05-29 A method for in vitro diagnosis of multiple sclerosis
PCT/PL2024/050037 WO2024248642A1 (en) 2023-05-29 2024-05-29 A method for in vitro diagnosis of multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445027A PL445027A1 (pl) 2023-05-29 2023-05-29 Sposób diagnozowania stwardnienia rozsianego in vitro

Publications (1)

Publication Number Publication Date
PL445027A1 true PL445027A1 (pl) 2024-12-02

Family

ID=92107003

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445027A PL445027A1 (pl) 2023-05-29 2023-05-29 Sposób diagnozowania stwardnienia rozsianego in vitro

Country Status (3)

Country Link
EP (1) EP4720674A1 (pl)
PL (1) PL445027A1 (pl)
WO (1) WO2024248642A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015070A2 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
US20080014600A1 (en) * 2002-08-29 2008-01-17 Immunosciences Lab., Inc. Diagnosis of multiple sclerosis and other demyelinating diseases
WO2011080349A1 (en) * 2010-01-04 2011-07-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Detection method of anti-myelin autoreactive t-cells and diagnostic method of autoimmune disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015070A2 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
US20080014600A1 (en) * 2002-08-29 2008-01-17 Immunosciences Lab., Inc. Diagnosis of multiple sclerosis and other demyelinating diseases
WO2011080349A1 (en) * 2010-01-04 2011-07-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Detection method of anti-myelin autoreactive t-cells and diagnostic method of autoimmune disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P. PIATEK ET AL.: "Cells. 2019 Dec 19;9(1):15", MULTIPLE SCLEROSIS CD49D+CD154+ AS MYELIN-SPECIFIC LYMPHOCYTES INDUCED DURING REMYELINATION. *
P. PIATEK ET AL.: "Cells. 2019 Nov 25; 8(12): 1508", MS CD49D+CD154+ LYMPHOCYTES REPROGRAM OLIGODENDROCYTES INTO IMMUNE REACTIVE CELLS AFFECTING CNS REGENERATION. *

Also Published As

Publication number Publication date
WO2024248642A1 (en) 2024-12-05
EP4720674A1 (en) 2026-04-08

Similar Documents

Publication Publication Date Title
Moellering Jr Linezolid: the first oxazolidinone antimicrobial
Gibb et al. Emotional, physical, and sexual maltreatment in childhood versus adolescence and personality dysfunction in young adulthood
Liu et al. Autoimmune encephalitis after Japanese encephalitis in children: a prospective study
Bruunsgaard et al. Clinical progression of HIV infection: role of NK cells
US9448229B2 (en) Kit for monitoring immune status after transplant and method for monitoring immune status using same
Yang et al. Low normal TSH levels and thyroid autoimmunity are associated with an increased risk of osteoporosis in euthyroid postmenopausal women
Bolaños et al. Remission of Graves’ hyperthyroidism treated with methimazole
Prado‐Drayer et al. Immunophenotype of peripheral T lymphocytes, NK cells and expression of CD69 activation marker in patients with recurrent spontaneous abortions, during the mid‐luteal phase
Riedel et al. A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort
Ketsamathi et al. Prevalence of thyroid dysfunction in Thai HIV-infected patients
Wada et al. False-positive TSH receptor antibody—a pitfall of third-generation TSH receptor antibody measurements in neonates—
Seidman et al. Is universal screening of ivf patients for SARS-CoV-2 justified?
Marron et al. Association of baseline sleep quality with trajectories of depressive symptoms in patients undergoing interferon treatment
Aryana et al. The relationship between follistatin and sarcopenia in elderly
Borderi et al. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large Italian cohort
Vashisth et al. Comparison of serum calcium levels in euthyroid, subclinical and overt hypothyroid women in the tribal belt of West Midnapore, West Bengal
Hoff et al. Signs of cellular immunosuppression correlate with HLA-DR phenotypes in healthy HIV-negative homosexuals: preliminary findings
Lindell et al. Impaired Lymphocyte Responses in Pediatric Sepsis Vary by Pathogen Type
JG et al. Intestinal tuberculosis. A diagnostic challenge
Bonifacio et al. Comparison of IA‐2 Bridge ELISA and Radiobinding Assays for Progression Risk Assessment in Early‐Stage Type 1 Diabetes
Takahashi et al. Short-Chain Fatty Acids May Promote Regulatory T Cell Induction to Enhance Maternal Immune Tolerance in Early Pregnancy
Agrawal et al. Effect of neonatal BCG vaccination on the evolution of Hashimoto’s Thyroiditis
Paolini et al. Effect of Neutrophil to Lymphocyte ratio on antidepressant treatment response: moderating effect of sex and mediating effect of Hippocampal volumes.
Kist et al. 43678 Poor value of annual tuberculosis screening in patients on biologics: an observational cohort study using the nationwide MarketScan database
McClure et al. 43505 Pityriasis Rosea Mimicked by Angioimmunoblastic T-Cell Lymphoma